A UK NEQAS ISH multicenter ring study using the Ventana HER2 dual-color ISH assay.

Hdl Handle:
http://hdl.handle.net/10147/229039
Title:
A UK NEQAS ISH multicenter ring study using the Ventana HER2 dual-color ISH assay.
Authors:
Bartlett, J M S; Campbell, Fiona M; Ibrahim, Merdol; O'Grady, Anthony; Kay, Elaine; Faulkes, Catherine; Collins, Nadine; Starczynski, Jane; Morgan, John M; Jasani, Bharat; Miller, Keith
Affiliation:
Endocrine Cancer Group, Edinburgh, Scotland.
Citation:
A UK NEQAS ISH multicenter ring study using the Ventana HER2 dual-color ISH assay. 2011, 135 (1):157-62 Am. J. Clin. Pathol.
Journal:
American journal of clinical pathology
Issue Date:
Jan-2011
URI:
http://hdl.handle.net/10147/229039
DOI:
10.1309/AJCPVPRKK1ENEDGQ
PubMed ID:
21173138
Additional Links:
http://ajcp.ascpjournals.org/content/135/1/157.full.pdf+html
Abstract:
We performed a multicenter assessment of a new HER2 dual-color chromogenic in situ hybridization (CISH) test and herein report on concordance of CISH data with fluorescence in situ hybridization (FISH) data and intraobserver and interlaboratory scoring consistency. HER2 results were evaluated using duplicate cores from 30 breast cancers in 5 laboratories using the Ventana HER2 dual-color ISH assay (Ventana Medical Systems, Cambridgeshire, England) and in 1 central laboratory using a standard FISH assay. Overall 93.3% of cases were successfully analyzed by CISH across the 5 participating laboratories. There was excellent concordance (98.0% overall) for diagnosis of HER2 amplification by CISH compared with FISH. Intraobserver variability (7.7%) and intersite variability (9.1%) of absolute HER2/chromosome enumeration probe 17 ratios were tightly controlled across all participating laboratories. The Ventana HER2 dual-color ISH assay is robust and reproducible, shows good concordance with a standard FISH assay, and complies with requirements in national and international guidelines for performance of ISH-based diagnostic tests.
Item Type:
Article
Language:
en
MeSH:
Adenocarcinoma; Breast Neoplasms; Chromosomes, Human, Pair 17; Female; Gene Expression Profiling; Great Britain; Humans; In Situ Hybridization, Fluorescence; Pathology, Clinical; Receptor, erbB-2; Tissue Array Analysis
ISSN:
1943-7722

Full metadata record

DC FieldValue Language
dc.contributor.authorBartlett, J M Sen_GB
dc.contributor.authorCampbell, Fiona Men_GB
dc.contributor.authorIbrahim, Merdolen_GB
dc.contributor.authorO'Grady, Anthonyen_GB
dc.contributor.authorKay, Elaineen_GB
dc.contributor.authorFaulkes, Catherineen_GB
dc.contributor.authorCollins, Nadineen_GB
dc.contributor.authorStarczynski, Janeen_GB
dc.contributor.authorMorgan, John Men_GB
dc.contributor.authorJasani, Bharaten_GB
dc.contributor.authorMiller, Keithen_GB
dc.date.accessioned2012-06-15T10:14:08Z-
dc.date.available2012-06-15T10:14:08Z-
dc.date.issued2011-01-
dc.identifier.citationA UK NEQAS ISH multicenter ring study using the Ventana HER2 dual-color ISH assay. 2011, 135 (1):157-62 Am. J. Clin. Pathol.en_GB
dc.identifier.issn1943-7722-
dc.identifier.pmid21173138-
dc.identifier.doi10.1309/AJCPVPRKK1ENEDGQ-
dc.identifier.urihttp://hdl.handle.net/10147/229039-
dc.description.abstractWe performed a multicenter assessment of a new HER2 dual-color chromogenic in situ hybridization (CISH) test and herein report on concordance of CISH data with fluorescence in situ hybridization (FISH) data and intraobserver and interlaboratory scoring consistency. HER2 results were evaluated using duplicate cores from 30 breast cancers in 5 laboratories using the Ventana HER2 dual-color ISH assay (Ventana Medical Systems, Cambridgeshire, England) and in 1 central laboratory using a standard FISH assay. Overall 93.3% of cases were successfully analyzed by CISH across the 5 participating laboratories. There was excellent concordance (98.0% overall) for diagnosis of HER2 amplification by CISH compared with FISH. Intraobserver variability (7.7%) and intersite variability (9.1%) of absolute HER2/chromosome enumeration probe 17 ratios were tightly controlled across all participating laboratories. The Ventana HER2 dual-color ISH assay is robust and reproducible, shows good concordance with a standard FISH assay, and complies with requirements in national and international guidelines for performance of ISH-based diagnostic tests.en_GB
dc.language.isoenen
dc.relation.urlhttp://ajcp.ascpjournals.org/content/135/1/157.full.pdf+htmlen_GB
dc.rightsArchived with thanks to American journal of clinical pathologyen_GB
dc.subject.meshAdenocarcinoma-
dc.subject.meshBreast Neoplasms-
dc.subject.meshChromosomes, Human, Pair 17-
dc.subject.meshFemale-
dc.subject.meshGene Expression Profiling-
dc.subject.meshGreat Britain-
dc.subject.meshHumans-
dc.subject.meshIn Situ Hybridization, Fluorescence-
dc.subject.meshPathology, Clinical-
dc.subject.meshReceptor, erbB-2-
dc.subject.meshTissue Array Analysis-
dc.titleA UK NEQAS ISH multicenter ring study using the Ventana HER2 dual-color ISH assay.en_GB
dc.typeArticleen
dc.contributor.departmentEndocrine Cancer Group, Edinburgh, Scotland.en_GB
dc.identifier.journalAmerican journal of clinical pathologyen_GB
dc.description.provinceLeinsteren

Related articles on PubMed

All Items in Lenus, The Irish Health Repository are protected by copyright, with all rights reserved, unless otherwise indicated.